Facing Calls For Compulsory Licensing, Roche To Provide Fuzeon In Korea Under Compassionate Access Program
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Nearly five years after refusing to supply its antiretroviral Fuzeon (enfuvirtide) to HIV/AIDS patients in South Korea due to pricing issues, Roche Korea says it will now provide the medication through its compassionate access program
You may also be interested in...
Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court
SEOUL - In what appears to be a victory - at least for now - for multinational pharma companies in their fight against mounting calls for price cuts, a Seoul Administrative Court maintained its earlier stance and ruled that a court-ordered price cut for Novartis' Glivec (imatinib) goes against "fairness" and the purpose of the EU free trade agreement
Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court
SEOUL - In what appears to be a victory - at least for now - for multinational pharma companies in their fight against mounting calls for price cuts, a Seoul Administrative Court maintained its earlier stance and ruled that a court-ordered price cut for Novartis' Glivec (imatinib) goes against "fairness" and the purpose of the EU free trade agreement
Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court
A mandated price cut for imatinib goes against "fairness" and the purpose of the EU free trade agreement, the court said.